Global Metachromatic Leukodystrophy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Metachromatic Leukodystrophy treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including ArmaGen Inc, Homology Medicines Inc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Takeda Pharmaceutical Company Ltd and others.
A Significant contribution to the Metachromatic Leukodystrophy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Metachromatic Leukodystrophy pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Metachromatic Leukodystrophy condition and increased access to investments is encouraging growth of Metachromatic Leukodystrophy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Metachromatic Leukodystrophy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Metachromatic Leukodystrophy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Metachromatic Leukodystrophy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Metachromatic Leukodystrophy. Further, orphan drug status, fast track designation, grants awarded and other special status for Metachromatic Leukodystrophy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Metachromatic Leukodystrophy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Metachromatic Leukodystrophy Pipeline candidates-
A Significant contribution to the Metachromatic Leukodystrophy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Metachromatic Leukodystrophy pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Metachromatic Leukodystrophy condition and increased access to investments is encouraging growth of Metachromatic Leukodystrophy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Metachromatic Leukodystrophy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Metachromatic Leukodystrophy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Metachromatic Leukodystrophy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Metachromatic Leukodystrophy. Further, orphan drug status, fast track designation, grants awarded and other special status for Metachromatic Leukodystrophy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Metachromatic Leukodystrophy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Metachromatic Leukodystrophy Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Metachromatic Leukodystrophy drugs
- Late phase: Phase 3 and in-approval Metachromatic Leukodystrophy drugs
- Company overview
- Snapshot
- Metachromatic Leukodystrophy therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Metachromatic Leukodystrophy- Disease Overview
2.2 Metachromatic Leukodystrophy- Pipeline Snapshot
2.3 Metachromatic Leukodystrophy- Pipeline Drugs by Phase
2.4 Metachromatic Leukodystrophy- Pipeline Drugs by Company
2.5 Metachromatic Leukodystrophy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 ArmaGen Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.2 Homology Medicines Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.3 Magenta Therapeutics Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.4 Orchard Therapeutics Ltd Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.5 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.6 RegenxBio Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.7 Takeda Pharmaceutical Company Ltd Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Metachromatic Leukodystrophy- Phase 1 Drug Details
4.2 Metachromatic Leukodystrophy- Phase 1 Drug Overview
4.3 Metachromatic Leukodystrophy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Metachromatic Leukodystrophy- Phase 2 Drug Details
5.2 Metachromatic Leukodystrophy- Phase 2 Drug Overview
5.3 Metachromatic Leukodystrophy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Metachromatic Leukodystrophy- Phase 3 Drug Details
6.2 Metachromatic Leukodystrophy- Phase 3 Drug Overview
6.3 Metachromatic Leukodystrophy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Metachromatic Leukodystrophy- Pre-clinical Phase Drug Details
7.2 Metachromatic Leukodystrophy- Pre-clinical Phase Drug Overview
7.3 Metachromatic Leukodystrophy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Metachromatic Leukodystrophy- Disease Overview
2.2 Metachromatic Leukodystrophy- Pipeline Snapshot
2.3 Metachromatic Leukodystrophy- Pipeline Drugs by Phase
2.4 Metachromatic Leukodystrophy- Pipeline Drugs by Company
2.5 Metachromatic Leukodystrophy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 ArmaGen Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.2 Homology Medicines Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.3 Magenta Therapeutics Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.4 Orchard Therapeutics Ltd Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.5 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.6 RegenxBio Inc Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
3.7 Takeda Pharmaceutical Company Ltd Metachromatic Leukodystrophy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Metachromatic Leukodystrophy- Phase 1 Drug Details
4.2 Metachromatic Leukodystrophy- Phase 1 Drug Overview
4.3 Metachromatic Leukodystrophy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Metachromatic Leukodystrophy- Phase 2 Drug Details
5.2 Metachromatic Leukodystrophy- Phase 2 Drug Overview
5.3 Metachromatic Leukodystrophy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Metachromatic Leukodystrophy- Phase 3 Drug Details
6.2 Metachromatic Leukodystrophy- Phase 3 Drug Overview
6.3 Metachromatic Leukodystrophy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Metachromatic Leukodystrophy- Pre-clinical Phase Drug Details
7.2 Metachromatic Leukodystrophy- Pre-clinical Phase Drug Overview
7.3 Metachromatic Leukodystrophy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
